De novo therapy with everolimus, low-dose ciclosporine a, basiliximab and steroid elimination in pediatric kidney transplantation

American Journal of Transplantation

Volumn 10, Issue 10, 2010, Pages 2349-2354

  Pape, L ^a   Offner, G ^a   Kreuzer, M ^a   Froede, K ^a   Drube, J ^a   Kanzelmeyer, N ^a   Ehrich, J H H ^a   Ahlenstiel, T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute allograft rejection; mTOR inhibitor; pediatric kidney transplantation; steroid withdrawal

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; FOLLITROPIN; GANCICLOVIR; LUTEINIZING HORMONE; PREDNISOLONE; TESTOSTERONE; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ANEMIA; APHTHOUS STOMATITIS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEIGHT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; OTITIS MEDIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RHINOPHARYNGITIS; SCHOOL CHILD; TONSILLITIS; URINARY TRACT INFECTION; VASCULAR DISEASE; VOMITING; WOUND HEALING IMPAIRMENT;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; MALE; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; SIROLIMUS; TREATMENT OUTCOME;

EID: 77957205634     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03266.x     Document Type: Article

References (28)

1. Joosten SA, Sijpkens W, van Kooten C, Paul LC. Chronic renal allograft rejection: Pathophysiologic considerations. Kidney Int 2005 68: 1 13. (Pubitemid 43181359)
2. Offner G, Toenshoff B, Höcker B et al. Efficacy and safety of Basiliximab in pediatric renal transplant patients receiving cyclosporine, mycopheolate mofetil and steroids. Transplantation 2008 86: 1241 1248.
3. https://web.emmes.com/study/ped/annlrept/annlrept.html. Accessed June 1, 2010.
4. Pape L, Ahlenstiel T, Ehrich JHH, Offner G. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to Everolimus and low-dose Cyclosporine A. Ped Transplant 2007 11: 291 295. (Pubitemid 46570146)
5. Gaumann A, Schlitt HJ, Geissler EK. Immunosuppression and tumor development in organ transplant recipients: The emerging dualistic role of rapamycin. Transplantation 2008 21: 207 217. (Pubitemid 351216959)
6. Ettenger R, Hoyer PF, Grimm P et al. Multicenter trial of Everolimus in pediatric renal transplant recipients: Results at three years. Pediatr Transplant 2008 12: 456 463. (Pubitemid 351652075)
7. Sutherland S, Li L, Concepcion W, Salvatierra O, Sarwal MM. Steroid-free immunosuppression in pediatric renal transplantation: Rationale outcomes following conversion to steroid based therapy. Transplantation 2009 87: 1744 1748.
8. Grenda R, Watson A, Trompeter R et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: The TWIST study. Am J Transplant 2010 10: 828 836.
9. Höcker B, Weber LT, Feneberg R et al. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil. Transplantation 2009 87: 934 941.
10. Li L, Chang A, Naesens M et al. Steroid-free immunosuppression since 1999: 129 Pediatric renal transplants with sustained graft and patient benefits. Am J Transplant 2009 9: 1362 1372.
11. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008 8: 753 760. (Pubitemid 351347767)
12. Schwartz GJ, Muñoz A, Schneider MF et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009 20: 629 637.
13. Jungraithmayr TC, Wiesmayr S, Staskewitz A et al. Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007 83: 900 905. (Pubitemid 46682730)
14. Vítko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005 5: 2521 2530. (Pubitemid 43919438)
15. Lorber MI, Mulgaonkar S, Butt KM et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005 80: 244 252. (Pubitemid 41061682)
16. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357: 2562 2575. (Pubitemid 350294223)
17. Ekberg H, Bernasconi C, Tedesco-Silva et al. Calcineurin inhibitor minimization in the symphony study: Observational results 3 years after transplantation. Am J Transplant 2009 9: 1876 1885.
18. Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-Year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007 83: 883 892. (Pubitemid 46682728)
19. Tenderich G, Fuchs U, Zittermann A et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007 21: 536 543. (Pubitemid 47161833)
20. Chapman JR, Valantine H, Albanell J. Proliferation signal inhibitors in transplantation: Questions at the cutting edge of everolimus therapy. Transplant Proc 2007 39: 2937 2950. (Pubitemid 350258649)
21. Hartford CM, Retain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007 82: 281 288.
22. Albano L, Berthoux F, Moal MC et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009 88: 69 76.
23. Hill JA, Hummel M, Starling RC et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007 84: 1436 1442. (Pubitemid 350294718)
24. Marty FM, Bryar J, Browne SK et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: A cohort analysis. Blood 2007 11: 490 500. (Pubitemid 47105386)
25. Alvarez-Garcia O, Carbajp-Perez E, Garcia E et al. Rapamycin retards growth and causes marked alterations in the growth plate of young rat. Pediatr Nephrol 2007 22: 954 961. (Pubitemid 46881913)
26. Sanchez CP, He YZ. Bone growth during rapamycin therapy in young rats. BMC Pediatr 2009 9: 3.
27. Rangel GA, Ariceta G. Growth failure associated with sirolimus: Case report. Pediatr Nephrol 2009 24: 2047 2050.
28. Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: An overview. Transplant Int 2007 20: 305 311. (Pubitemid 46310629)